Becton Dickinson and Co (BDX)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013536)
◆英語タイトル:Becton Dickinson and Co (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013536
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:103
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Becton Dickinson and Co (BD) is a medical technology company that manufactures and sells medical devices, reagents and instrument. Its major products include syringes and pen needles; intravenous catheters; infusion pumps and disposables; automated medication dispensing and supply management systems; prefillable drug delivery systems; respiratory ventilation and diagnostics equipment and consumables; products for the safe collection and transport of diagnostics specimens; instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infectionsand cancers and various clinical research tools. BD offers its products to life science researchers, healthcare institutions, clinical laboratories, pharmaceutical industry and general public. The company sells its products in the Americas, Europe, the Middle East, Africa and Asia-Pacific. BD is headquartered in New Jersey, the US.

Becton Dickinson and Co (BDX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Becton Dickinson and Co, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Becton Dickinson and Co, Medical Devices Deals, 2011 to YTD 2017 11
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
GenCell Biosystems Raises US$3.5 Million In Seed Financing Round 16
Sirigen Secures US$3 Million In Venture Financing 17
Private Equity 18
CareFusion Reportedly Elicits Acquisition Interest From Private Equity Firms 18
Partnerships 19
Selah Genomics, Greenville Health, DecisionQ and Becton Dickinson Enter into Agreement 19
GenCell Biosystems To Enter Into Agreement With Fiocruz, Institute Of Molecular Biology Of Parana And Immunobiological Technology Institute To Develop Clinical Screening Systems 20
Sartorius Stedim Biotech Enters Into Co-Development Agreement With BD Diagnostic 21
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 22
TCGRx Enters Into Co-Marketing Agreement With CareFusion For Medication Delivery Solutions 23
CareFusion Enters Into Distribution Agreement With ResMed 24
SANYO North America Enters Into Co-Promotion Agreement With BD Biosciences 25
Licensing Agreements 26
Advanced Inhalation Therapies Enters into Licensing Agreement with CareFusion 26
Equity Offering 27
Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 27
Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 29
Becton, Dickinson Files Registration Statement For Public Offering Of Securities 31
Debt Offering 32
Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 32
Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 33
Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 34
Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 35
Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 36
Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 37
Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 38
Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 39
Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 40
Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 42
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 1.8% Notes Due 2017 44
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 2.675% Notes Due 2019 46
Becton, Dickinson Raises USD1.75 Billion in Public Offering of 3.734% Notes Due 2024 48
Becton, Dickinson Raises USD1.2 Billion in Public Offering of 4.685% Notes Due 2044 50
Becton, Dickinson Raises USD750 Million in Public Offering of Floating Rate Notes Due 2016 52
CareFusion Raises USD300 Million in Private Placement of Notes Due 2017 54
CareFusion Raises USD400 Million in Public Offering of Notes Due 2024 56
CareFusion Raises USD300 Million in Public Offering of Notes Due 2044 57
CareFusion Completes Private Placement Of Notes Due 2023 For US$300 Million 58
Becton, Dickinson Completes Public Offering Of Notes Due 2016 For US$500 Million 59
Becton, Dickinson Completes Public Offering Of Notes Due 2021 For US$1 Billion 60
Asset Transactions 61
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 61
Acquisition 62
BD Acquires CRISI Medical Systems 62
Becton, Dickinson Acquires GenCell Biosystems 63
Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 64
Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions 66
Becton Dickinson and Co – Key Competitors 67
Becton Dickinson and Co – Key Employees 68
Becton Dickinson and Co – Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Recent Developments 77
Strategy And Business Planning 77
Jan 26, 2017: New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes Through Collaboration 77
Financial Announcements 78
Aug 03, 2017: BD Announces Results For 2017 Third Fiscal Quarter 78
May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter 80
Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter 82
Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance 84
Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter 86
May 05, 2016: BD Announces Results For 2016 Second Fiscal Quarter 88
Feb 03, 2016: BD Announces Results For 2016 First Fiscal Quarter 90
Corporate Communications 92
Apr 23, 2017: BD Announces Appointment Of Tom Polen As President 92
Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors 93
Legal and Regulatory 94
Aug 18, 2017: District Court Issues Final Judgment – Retractable Technologies v. Becton, Dickinson 94
Mar 21, 2017: Retractable Technologies Announces Litigation Updates 95
Government and Public Interest 96
Jun 06, 2017: BD Releases 2016 Sustainability Report 96
Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management 97
Product News 98
Sep 12, 2017: BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis 98
Feb 08, 2016: BD Launches BD FACSymphony High-Speed Cell Analyzer to Enable Identification and Analysis of Rare Cell Types 99
Jan 17, 2017: BD Launches Reagents to Simplify Single Cell Research 100
Other Significant Developments 101
Apr 03, 2017: BD Launches “Power in Prevention” Program to Help Minimize Risk of Infections during Surgical Process at 2017 AORN Annual Conference 101
Feb 16, 2017: BD Initiates New Industry Alliance To Combat Rising Opioid Crisis 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103

List of Tables
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Becton Dickinson and Co, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Becton Dickinson and Co, Deals By Therapy Area, 2011 to YTD 2017 10
Becton Dickinson and Co, Medical Devices Deals, 2011 to YTD 2017 11
Becton Dickinson and Co, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
GenCell Biosystems Raises US$3.5 Million In Seed Financing Round 16
Sirigen Secures US$3 Million In Venture Financing 17
CareFusion Reportedly Elicits Acquisition Interest From Private Equity Firms 18
Selah Genomics, Greenville Health, DecisionQ and Becton Dickinson Enter into Agreement 19
GenCell Biosystems To Enter Into Agreement With Fiocruz, Institute Of Molecular Biology Of Parana And Immunobiological Technology Institute To Develop Clinical Screening Systems 20
Sartorius Stedim Biotech Enters Into Co-Development Agreement With BD Diagnostic 21
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 22
TCGRx Enters Into Co-Marketing Agreement With CareFusion For Medication Delivery Solutions 23
CareFusion Enters Into Distribution Agreement With ResMed 24
SANYO North America Enters Into Co-Promotion Agreement With BD Biosciences 25
Advanced Inhalation Therapies Enters into Licensing Agreement with CareFusion 26
Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 27
Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 29
Becton, Dickinson Files Registration Statement For Public Offering Of Securities 31
Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 32
Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 33
Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 34
Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 35
Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 36
Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 37
Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 38
Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 39
Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 40
Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 42
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 1.8% Notes Due 2017 44
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 2.675% Notes Due 2019 46
Becton, Dickinson Raises USD1.75 Billion in Public Offering of 3.734% Notes Due 2024 48
Becton, Dickinson Raises USD1.2 Billion in Public Offering of 4.685% Notes Due 2044 50
Becton, Dickinson Raises USD750 Million in Public Offering of Floating Rate Notes Due 2016 52
CareFusion Raises USD300 Million in Private Placement of Notes Due 2017 54
CareFusion Raises USD400 Million in Public Offering of Notes Due 2024 56
CareFusion Raises USD300 Million in Public Offering of Notes Due 2044 57
CareFusion Completes Private Placement Of Notes Due 2023 For US$300 Million 58
Becton, Dickinson Completes Public Offering Of Notes Due 2016 For US$500 Million 59
Becton, Dickinson Completes Public Offering Of Notes Due 2021 For US$1 Billion 60
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 61
BD Acquires CRISI Medical Systems 62
Becton, Dickinson Acquires GenCell Biosystems 63
Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 64
Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions 66
Becton Dickinson and Co, Key Competitors 67
Becton Dickinson and Co, Key Employees 68
Becton Dickinson and Co, Other Locations 70
Becton Dickinson and Co, Subsidiaries 71

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Becton Dickinson and Co (BDX)-製薬・医療分野:企業M&A・提携分析(Becton Dickinson and Co (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆